 Cellular Biomedicine Group Inc. NASDAQ: CBMG CBMG or the Company, a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies, announced early data from its ongoing investigator initiated trial IIT at an oral presentation titled Novel Anti-BCMA CAR-T for Relapsed or Refractory Multiple Myeloma at the 61st American Society of Hematology ASH annual meeting on December 7, 2019 in Orlando, Florida. 